請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/98057完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃恆獎 | zh_TW |
| dc.contributor.advisor | Heng-Chiang Huang | en |
| dc.contributor.author | 馮韞志 | zh_TW |
| dc.contributor.author | William Y. Feng | en |
| dc.date.accessioned | 2025-07-23T16:37:34Z | - |
| dc.date.available | 2025-07-24 | - |
| dc.date.copyright | 2025-07-23 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-07-20 | - |
| dc.identifier.citation | 1. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323 (9) :844–853. doi:10.1001/jama.2020.1166
2. Harrer, S. (2020). Artificial Intelligence for Clinical Trial Design. Trends in Pharmacological Sciences. https://doi.org/10.1109/spmb50085.2020.9353614 3. Kim, E., Yang, J., Park, S., & Shin, K. (2023). Factors affecting success of new drug clinical trials. Therapeutic Innovation & Regulatory Science, 57 (4),737–750. https://doi.org/10.1007/s43441-023-00509-1 4. The Harvard Law School Forum on Corporate Governance [ohn P. Kelsh, Holly J. Gregory, and Rebecca Grapsas, Sidley Austin LLP]. (2017, November 29). Analysis of ISS’ QualityScore updates. The Harvard Law School Forum. https://corpgov.law.harvard.edu/2017/11/29/analysis-of-iss-qualityscore-updates/ 5. Sanchez, K. (2024, October 30). Governance QualityScore | ISS. ISS. https://www.issgovernance.com/esg/ratings/governance-qualityscore/ 6. Bauwhede, H. V. (2009). On the relation between corporate governance compliance and operating performance. Accounting and Business Research, 39 (5),497-513. 7. Brown, L. D., & Caylor, M. L. (2009). Corporate governance and firm operating performance. Review of quantitative finance and accounting, 32, 129-144. 8. Freeman, R. E. (1984). Strategic management: A stakeholder approach. Boston: Pitman. 9. R. Edward Freeman, Andrew C. Wicks, Bidhan Parmar, (2004) Stakeholder Theory and 「The Corporate Objective Revisited」. Organization Science 15 (3) :364-369. 10. Larcker, D., & Tayan, B. (2020). Corporate governance matters. FT Press. 11. Mallin, C. A. (2016). Corporate governance. Oxford university press. 12. Gompers, P., Ishii, J., & Metrick, A. (2003). Corporate governance and equity prices. The quarterly journal of economics, 118 (1),107-156. 13. Hosono, K., Tomiyama, M., & Miyagawa, T. (2004). Corporate governance and research and development: evidence from Japan. Economics of Innovation and New Technology, 13 (2),141-164. 14. Jermias, J. (2007). The effects of corporate governance on the relationship between innovative efforts and performance. European Accounting Review, 16 (4),827-854. 15. Rodrigues, R., Samagaio, A., & Felício, T. (2020). Corporate governance and R&D investment by European listed companies. Journal of Business Research, 115, 289-295. 16. Shapiro, D., Tang, Y., Wang, M., & Zhang, W. (2015). The effects of corporate governance and ownership on the innovation performance of Chinese SMEs. Journal of Chinese Economic and Business Studies, 13 (4),311-335. 17. Herrmann, P., Kaufmann, J., & van Auken, H. (2010). The role of corporate governance in R&D intensity of US‐based international firms. International Journal of Commerce and Management, 20 (2),91-108. 18. Honoré, F., Munari, F., & de La Potterie, B. V. P. (2015). Corporate governance practices and companies’ R&D intensity: Evidence from European countries. Research policy, 44 (2),533-543. 19. Muhammad, H., Migliori, S., & Consorti, A. (2024). Corporate governance and R&D investment: does firm size matter? Technology Analysis & Strategic Management, 36 (3),518-532. 20. Huang, C. J. (2010). Corporate governance, corporate social responsibility and corporate performance. Journal of management & organization, 16 (5),641-655. 21. Moir, L. (2001). What do we mean by corporate social responsibility? Corporate Governance: The international journal of business in society, 1 (2),16-22. 22. Jo, H., & Harjoto, M. A. (2012). The causal effect of corporate governance on corporate social responsibility. Journal of business ethics, 106, 53-72. 23. Ruangviset, J., Jiraporn, P., & Kim, J. C. (2014). How does corporate governance influence corporate social responsibility? Procedia-Social and Behavioral Sciences, 143, 1055-1057. 24. Wang, D., Zhu, Q., Avolio, B. J., Shen, W., & Waldman, D. (2023). Do employees' views matter in corporate governance? The relationship between employee approval and CEO dismissal. Strategic Management Journal, 44 (5),1328-1354. 25. Dube, S., & Zhu, C. (2021). The disciplinary effect of social media: Evidence from firms' responses to Glassdoor reviews. Journal of Accounting Research, 59 (5),1783-1825. 26. Holznienkemper, L. (2024, May 4). Glassdoor Review 2024: features, pros & cons. Forbes Advisor. https://www.forbes.com/advisor/business/glassdoor-review/ 27. Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20 (2),273-286. 28. Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemporary clinical trials communications, 11, 156-164. 29. Piantadosi, S. (2024). Clinical trials: a methodologic perspective. John Wiley & Sons. 30. NIH’s definition of a clinical trial. (2014). National Institutes of Health. Retrieved October 31, 2024, from https://grants.nih.gov/policy-and-compliance/policy-topics/clinical-trials/definition#:~:text=Clinical%20Trial%20Stewardship.-,NIH%20Definition%20of%20a%20Clinical%20Trial,related%20biomedical%20or%20behavioral%20outcomes. 31. Basics About Clinical Trials. (2024). FDA.gov. Retrieved October 29, 2024, from https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinical-trials 32. SEC About. (2024).US Securities Exchange Commission. Retrieved October 29, 2024, from https://www.sec.gov/about 33. FDA Mission. (2024). FDA.gov. Retrieved October 29, 2024, from https://www.fda.gov/about-fda/what-we-do 34. Veloso-Beltran, D. (2024, May 21). About ISS | ISS. ISS. https://www.issgovernance.com/about/about-iss/ 35. The Harvard Law School Forum on Corporate Governance. (2021, February 25). QualityScore: Methodology Guide. https://corpgov.law.harvard.edu/2021/02/25/qualityscore-methodology-guide/ 36. ISS Corporate Governance QualityScore in Yahoo Finance company profiles. (2024). Yahoo Finance. Retrieved October 29, 2024, from https://help.yahoo.com/kb/SLN2369.html 37. Frequently asked questions about ESG. (2024). csrhub.com. Retrieved October 29, 2024, from https://www.csrhub.com/frequently-asked-questions-about-esg 38. Matakanye, R. M., van der Poll, H. M., & Muchara, B. (2021). Do companies in different industries respond differently to stakeholders’ pressures when prioritising environmental, social and governance sustainability performance? Sustainability, 13 (21),12022. 39. Musa, H., Krištofik, P., Lysenko, Y., & Medzihorsky, J. (2024). Is there a connection between ESG scores and a company's profitability? Empirical evidence on selected Stoxx Europe 600 firms. Investment Management & Financial Innovations, 21 (3),344. 40. Research Rebels. (2024, February 27). Endogeneity explained: Tackling hidden variables in your research. https://research-rebels.com/blogs/rebelsblog/endogeneity-explained-tackling-hidden-variables-in-your-research 41. Mogstad, M., Torgovitsky, A., & Walters, C. R. (2021). The causal interpretation of two-stage least squares with multiple instrumental variables. American Economic Review, 111 (11),3663-3698. 42. Sauro, J., PhD, & Lewis, J., PhD. (2023). Sample sizes for comparing rating scale means – MeasuringU. https://measuringu.com/sample-sizes-for-rating-scale-comparisons/ 43. Comprehensive R Archive Network (CRAN). (2024, September 28). Applied Econometrics with R [R package AER version 1.2-14]. https://cran.r-project.org/web/packages/AER/index.html 44. Narayanan, S., & Pradhan, S. K. (2023). Analysing Corporate Governance Research in the Pharmaceutical Industry: A Bibliometric Study. Qubahan Academic Journal, 3 (4),437-456. 45. Friedman, L. M. (2015). Fundamentals of clinical trials. springer. 46. Premature Termination or Suspension of a Clinical Trial. (2023, October 2). https://www.niaid.nih.gov/. Retrieved January 27, 2025, from https://www.niaid.nih.gov/sites/default/files/score-premature-termination-or-suspension-of-clinical-trial.pdf 47. Policy and Guidance: Suspension and Termination of Research. (2021, March 15). ora.research.ucla.edu. Retrieved January 27, 2025, from https://ora.research.ucla.edu/OHRPP/Documents/Policy/11/Suspension_Termination.pdf 48. Gensler, G. (2025, January 17). Office Hours with Gary Gensler: Corporate Governance. SEC.GOV. Retrieved January 27, 2025, from https://www.sec.gov/newsroom/speeches-statements/sec-chair-gary-gensler-corporate-governance 49. Johnson, Michael & Cao, Jiongyi & Kang, Hyunseung. (2019). Detecting Heterogeneous Treatment Effect with Instrumental Variables. 10.48550/arXiv.1908.03652. 50. ClinicalTrials.gov – What, why, which studies, when | Office of Human Research Affairs. (n.d.). © 2025 Boston University. https://www.bumc.bu.edu/ohra/clinicaltrials-gov/clinicaltrials-gov-what-why-which-studies-when/ 51. Card, D. (1993). Using geographic variation in college proximity to estimate the return to schooling. 52. Nair, S. C., AlGhafli, S., & AlJaberi, A. (2018). Developing a clinical trial governance framework for pharmaceutical industry-funded clinical trials. Accountability in Research, 25 (7-8),373-386. 53. Angrist, J. D., & Pischke, J.-S. (2009). Mostly Harmless Econometrics: An Empiricist's Companion. Princeton University Press. 54. Bound, J., Brown, C., & Mathiowetz, N. (2001)."Measurement Error in Survey Data." In Handbook of Econometrics (Vol. 5, pp. 3705-3843). Elsevier. 55. Stock, J. H., & Watson, M. W. (2015). Introduction to Econometrics (3rd ed.). Pearson. 56. Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics, 20 (2),273-286. 57. Chaudhari, N., Ravi, R., Gogtay, N. J., & Thatte, U. M. (2020). Recruitment and retention of the participants in clinical trials: challenges and solutions. Perspectives in clinical research, 11 (2),64-69. 58. Dickson, M., & Gagnon, J. P. (2004). Key factors in the rising cost of new drug discovery and development. Nature reviews Drug discovery, 3 (5),417-429. 59. Getz, K. A., Campo, R. A., & Kaitin, K. I. (2011). Variability in protocol design complexity by phase and therapeutic area. Drug information journal: DIJ/Drug Information Association, 45 (4),413-420. 60. Lazonick, W., Hopkins, M., Jacobson, K., Sakinç, M. E., & Tulum, Ö. (2017).US pharma's financialized business model. Institute for New Economic Thinking Working Paper Series, (60). 61. Sertkaya, A., Wong, H. H., Jessup, A., & Beleche, T. (2016). Key cost drivers of pharmaceutical clinical trials in the United States. Clinical Trials, 13 (2),117-126. 62. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of health economics, 47, 20-33. 63. Suresh, K. P., & Chandrashekara, S. (2012). Sample size estimation and power analysis for clinical research studies. Journal of human reproductive sciences. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/98057 | - |
| dc.description.abstract | 本研究深入分析了公司治理品質與製藥公司臨床試驗進展之間的相關性。從理論框架、文獻綜述、和實證結果等方面，探討了公開可用的公司治理資訊是否可以用於預測藥物開發臨床試驗的進展，同時考慮潛在的混淆變數和內生性問題。研究結果表明，公司治理質量與臨床試驗進展之間存在顯著相關性。公司治理評分最好的新藥研發公司與最差的公司之間，臨床試驗達成率可能相差超過34%， 公司治理影響臨床試驗達成率的因果關係顯著，存在相反因果關係的可能性不顯著。本研究為投資者和公司治理相關的學術研究提供了有價值的參考。 | zh_TW |
| dc.description.abstract | This study thoroughly analyzes the correlation between corporate governance quality and the progress of pharmaceutical companies' clinical trials. From the perspectives of theoretical framework, literature review, and empirical results, it explores whether publicly available corporate governance information can be used to predict the progress of drug development clinical trials, while considering potential confounding variables and endogeneity issues. The research findings indicate a significant correlation between corporate governance quality and the progress of clinical trials. Between new drug development companies with the best and worst corporate governance scores, the clinical trial achievement rate may differ by more than 34%. The causal relationship of corporate governance affecting the clinical trial achievement rate is significant, while the possibility of a reverse causal relationship is not significant. This study provides valuable references for investors and academic research related to corporate governance. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-07-23T16:37:34Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-07-23T16:37:34Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
序言與謝辭 ii 中文摘要 iii Abstract iv 目次 v 圖次 vii 第一章：緒論 1 第一節 研究背景、動機、與缺口 1 第二節 研究目的與理論框架 4 第三節 研究範圍 5 第四節 論文架構 5 第二章：文獻回顧 7 第一節 影響臨床試驗達成度傳統因素 7 第二節 公司治理 11 第三節 公司治理與研發績效關係之學術研究 12 第四節 公司治理與企業社會責任的關係 15 第五節 公司治理與員工意見的關係 16 第六節 ISS Governance & QualityScore 17 第七節 CSRHub ESG Ranking Score 18 第三章：研究方法 20 第一節 工具變量與多重工具變量 20 第二節 研究假設 22 第三節 資料來源及收集 23 第四節 變數定義與數據建構 25 第五節 模型建立 26 第六節 分析方法 27 第四章：研究結果 29 第一節 數據概覽 29 第二節 迴歸分析 30 第三節 假設驗證 34 第五章：結論與建議 36 參考文獻 38 | - |
| dc.language.iso | zh_TW | - |
| dc.title | 公司治理品質與製藥公司臨床試驗達成率相關性之實證研究 | zh_TW |
| dc.title | An Empirical Study on the Correlation Between the Quality of Corporate Governance and the Achievement Rate of Clinical Trials in Pharmaceutical Companies | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.coadvisor | 胡凱焜 | zh_TW |
| dc.contributor.coadvisor | Kae kuen Hu | en |
| dc.contributor.oralexamcommittee | 潘令妍;王仕茹 | zh_TW |
| dc.contributor.oralexamcommittee | Ling-Yen Pan;Shih-Ju Wang | en |
| dc.subject.keyword | 公司治理,臨床試驗,ISS Governance QualityScore,CSRHub ESG Ranking,Glassdoor rating,工具變量,兩階段最小平方法, | zh_TW |
| dc.subject.keyword | Corporate Governance,Clinical Trail,ISS Governance QualityScore,CSRHub ESG Ranking,Glassdoor rating,Instrumental Variables,Two-Stage Least Square Method (2SLS), | en |
| dc.relation.page | 44 | - |
| dc.identifier.doi | 10.6342/NTU202501398 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2025-07-21 | - |
| dc.contributor.author-college | 進修推廣學院 | - |
| dc.contributor.author-dept | 生物科技管理碩士在職學位學程 | - |
| dc.date.embargo-lift | 2030-06-29 | - |
| 顯示於系所單位： | 生物科技管理碩士在職學位學程 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 此日期後於網路公開 2030-06-29 | 2.92 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。